Genzyme Corporation - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 86 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "Genzyme Corporation - Product Pipeline Review - 2014" provides data on the Genzyme Corporation's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Genzyme Corporation's corporate website, SEC filings, investor presentations and featured press releases, both from Genzyme Corporation and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- Genzyme Corporation - Brief Genzyme Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Genzyme Corporation human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Genzyme Corporation with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Genzyme Corporation's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Genzyme Corporation's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Genzyme Corporation in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Genzyme Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Genzyme Corporation.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Genzyme Corporation and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Genzyme Corporation Snapshot 6
Genzyme Corporation Overview 6
Key Information 6
Key Facts 6
Genzyme Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Genzyme Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Genzyme Corporation - Pipeline Products Glance 14
Genzyme Corporation - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Filing rejected/Withdrawn Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Genzyme Corporation - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Genzyme Corporation - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Genzyme Corporation - Unknown Stage Pipeline Products 21
Unknown Products/Combination Treatment Modalities 21
Genzyme Corporation - Drug Profiles 22
eliglustat tartrate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
alemtuzumab 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
mipomersen sodium 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
fresolimumab 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GZ-402665 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Genz-682452 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GZ-402663 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GZ-402666 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
GZ-404477 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
1D-11 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GENZ-644442 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GENZ-668764 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NsG-33 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RNase H-Active Antisense Oligos 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Malaria Program 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
patisiran 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Genzyme Corporation - Pipeline Analysis 43
Genzyme Corporation - Pipeline Products by Therapeutic Class 43
Genzyme Corporation - Pipeline Products by Target 46
Genzyme Corporation - Pipeline Products by Route of Administration 48
Genzyme Corporation - Pipeline Products by Molecule Type 49
Genzyme Corporation - Pipeline Products by Mechanism of Action 51
Genzyme Corporation - Recent Pipeline Updates 53
Genzyme Corporation - Dormant Projects 70
Genzyme Corporation - Discontinued Pipeline Products 73
Discontinued Pipeline Product Profiles 73
ataluren 73
Genz-644470 73
GZ-402674 73
metelimumab 73
teriflunomide 74
Genzyme Corporation - Locations And Subsidiaries 75
Head Office 75
Other Locations & Subsidiaries 75
Genzyme Corporation - Key Manufacturing Facilities 84
Appendix 85
Methodology 85
Coverage 85
Secondary Research 85
Primary Research 85
Expert Panel Validation 85
Contact Us 86
Disclaimer 86

List of Tables
Genzyme Corporation, Key Information 6
Genzyme Corporation, Key Facts 6
Genzyme Corporation - Pipeline by Indication, 2014 8
Genzyme Corporation - Pipeline by Stage of Development, 2014 10
Genzyme Corporation - Monotherapy Products in Pipeline, 2014 11
Genzyme Corporation - Partnered Products in Pipeline, 2014 12
Genzyme Corporation - Partnered Products/ Combination Treatment Modalities, 2014 13
Genzyme Corporation - Pre-Registration, 2014 14
Genzyme Corporation - Filing rejected/Withdrawn, 2014 15
Genzyme Corporation - Phase III, 2014 16
Genzyme Corporation - Phase II, 2014 17
Genzyme Corporation - Phase I, 2014 18
Genzyme Corporation - Preclinical, 2014 19
Genzyme Corporation - Discovery, 2014 20
Genzyme Corporation - Unknown, 2014 21
Genzyme Corporation - Pipeline by Therapeutic Class, 2014 44
Genzyme Corporation - Pipeline by Target, 2014 47
Genzyme Corporation - Pipeline by Route of Administration, 2014 48
Genzyme Corporation - Pipeline by Molecule Type, 2014 50
Genzyme Corporation - Pipeline Products by Mechanism of Action, 2014 52
Genzyme Corporation - Recent Pipeline Updates, 2014 53
Genzyme Corporation - Dormant Developmental Projects,2014 70
Genzyme Corporation - Discontinued Pipeline Products, 2014 73
Genzyme Corporation, Other Locations 75
Genzyme Corporation, Subsidiaries 81
Genzyme Corporation, Key Manufacturing Facilities 84